|
|
Volumn 8, Issue 12, 2007, Pages 1044-1045
|
|
Translation, please
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTHRACYCLINE;
AROMATASE INHIBITOR;
CYCLOPHOSPHAMIDE;
DOCETAXEL;
DOXORUBICIN;
EPIDERMAL GROWTH FACTOR RECEPTOR 2;
EPIRUBICIN;
ESTROGEN RECEPTOR;
FLUOROURACIL;
TAMOXIFEN;
TAXANE DERIVATIVE;
TRASTUZUMAB;
ADJUVANT THERAPY;
BREAST CANCER;
BREAST CARCINOMA;
CANCER INCIDENCE;
CLINICAL TRIAL;
DOSE RESPONSE;
DRUG CHOICE;
DRUG RESPONSE;
DRUG SENSITIVITY;
DRUG TARGETING;
GENE EXPRESSION;
GENETIC HETEROGENEITY;
HISTOPATHOLOGY;
HUMAN;
LETTER;
MOLECULAR BIOLOGY;
MULTIPLE CYCLE TREATMENT;
PRIORITY JOURNAL;
PROGNOSIS;
PROTEIN ANALYSIS;
RISK BENEFIT ANALYSIS;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
BREAST NEOPLASMS;
CHEMOTHERAPY, ADJUVANT;
CYCLOPHOSPHAMIDE;
DISEASE-FREE SURVIVAL;
EPIRUBICIN;
FEMALE;
FLUOROURACIL;
GENE EXPRESSION PROFILING;
GENE EXPRESSION REGULATION, NEOPLASTIC;
GENETIC SCREENING;
HUMANS;
NEOADJUVANT THERAPY;
NEOPLASM STAGING;
OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS;
PATIENT SELECTION;
PREDICTIVE VALUE OF TESTS;
RECEPTORS, ESTROGEN;
REPRODUCIBILITY OF RESULTS;
RESEARCH DESIGN;
SENSITIVITY AND SPECIFICITY;
TAXOIDS;
TREATMENT OUTCOME;
|
|
EID: 36549088121
PISSN: 14702045
EISSN: None
Source Type: Journal
DOI: 10.1016/S1470-2045(07)70349-2 Document Type: Letter |
|
Times cited : (1)
|
|
References (7)
|
